RecruitingEarly Phase 1NCT05057806

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Studying Infantile neuroaxonal dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The University of Texas Health Science Center at San Antonio
Principal Investigator
Carolina Solis-Herrera, MD
The University of Texas Health Science Center at San Antonio
Intervention
Empagliflozin 25 MG(drug)
Enrollment
30 target
Eligibility
18-80 years · All sexes
Timeline
20212027

Study locations (1)

Collaborators

Doris Duke Charitable Foundation · Max and Minnie Tomerlin Voelcker Fund

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05057806 on ClinicalTrials.gov

Other trials for Infantile neuroaxonal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Infantile neuroaxonal dystrophy

← Back to all trials